Oncology Pharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2013	FY 2011	FY 2004	FY 2003	FY 2002
Period Ending	Mar '13 Mar 31, 2013	Jun '11 Jun 30, 2011	Mar '04 Mar 31, 2004	Mar '03 Mar 31, 2003	Mar '02 Mar 31, 2002
Revenue	0.01	0.13	1.18	3.28	3.67
Revenue Growth (YoY)	-92.42%	-88.59%	-63.99%	-10.67%	-8.48%
Cost of Revenue	-	-	0.65	1.21	1.36
Gross Profit	0.01	0.13	0.53	2.07	2.31
Selling, General & Admin	0.02	0.02	1.85	2.91	3.56
Research & Development	-	-	0.38	0.66	0.77
Operating Expenses	0.02	0.08	2.23	3.57	4.33
Operating Income	-0.01	0.06	-1.7	-1.5	-2.02
Interest & Investment Income	-	-	0.01	0.02	0.09
Currency Exchange Gain (Loss)	-	-	-	0.09	-
Other Non Operating Income (Expenses)	-	-	-0.01	-	-0.02
EBT Excluding Unusual Items	-0.01	0.06	-1.71	-1.4	-1.95
Gain (Loss) on Sale of Assets	-	-	0.14	-	-
Asset Writedown	-	-	-	-0.12	-
Pretax Income	-0.01	0.06	-1.57	-1.52	-1.95
Income Tax Expense	0	0	-	-	-
Earnings From Continuing Operations	-0.02	0.06	-1.57	-1.52	-1.95
Earnings From Discontinued Operations	0.2	-	-	-	-
Net Income	0.19	0.06	-1.57	-1.52	-1.95
Net Income to Common	0.19	0.06	-1.57	-1.52	-1.95
Net Income Growth	216.79%	-	-	-	-
Free Cash Flow	0	-	-2.02	-1.59	-1.77
Gross Margin	100.00%	100.00%	44.62%	63.05%	63.02%
Operating Margin	-141.66%	44.19%	-144.03%	-45.85%	-54.90%
Profit Margin	1821.37%	43.60%	-132.52%	-46.34%	-53.13%
Free Cash Flow Margin	7.25%	-	-170.79%	-48.51%	-48.28%
EBITDA	-0.01	-	-1.62	-1.11	-1.68
EBITDA Margin	-84.69%	-	-137.17%	-33.81%	-45.62%
D&A For EBITDA	0.01	-	0.08	0.4	0.34
EBIT	-0.01	0.06	-1.7	-1.5	-2.02
EBIT Margin	-141.66%	44.19%	-144.03%	-45.85%	-54.90%
Effective Tax Rate	-	1.34%	-	-	-
Revenue as Reported	-	-	1.18	3.28	3.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.